Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock

Ken Griffin’s Citadel Advisors increased its Eli Lilly stake by 291% in Q2 to about $1.1B (8th-largest holding), while Druckenmiller’s Duquesne Family Office initiated a new position buying 12,380 shares after having exited in Q3 2025. The article attributes the buys to Lilly’s strong revenue/earnings growth tied to Mounjaro and Zepbound, with the stock having dropped as much as 23% below its late-April high. Overall, the signal is constructive for LLY but framed as conviction-by-investor strategy rather than a fresh earnings catalyst.

Analysis

This is more useful as a sentiment/flow signal than as fresh fundamentals. When high-conviction hedge funds add size after a drawdown, it often marks a valuation reset, not a change in the earnings trajectory; that can support the stock over the next few weeks, but it does not eliminate the risk that the multiple still has to de-rate if growth normalizes.

The bigger second-order issue is competitive positioning in obesity/diabetes. If Lilly keeps extending share, the pressure moves downstream to adjacent players that depend on a slower GLP-1 rollout, including peer pharma names with competing incretin pipelines and parts of the specialty-pharmacy / dispensing ecosystem that benefit from high prescription velocity. The most important structural optionality is the oral obesity franchise: if that gets validated, it increases the duration of the growth story and makes the current premium look less cyclical.

The contrarian risk is that consensus may be extrapolating too much from visible near-term demand while underweighting supply normalization, payer pushback, and the possibility that the market has already priced in most of the share gains. The stock can work if the next 1-2 earnings prints confirm volume and pricing, but a single guidance miss on prescription growth or manufacturing cadence would be enough to re-open the valuation debate. This is a medium-term thesis, not a quick catalyst trade.

Key Decisions for Investors

• Maintain a tactical long bias in LLY only on pullbacks; prefer adding on 5-8% weakness over chasing strength, with a 1-3 month hold tied to the next earnings/guide update.
• Pair trade idea: long LLY / short NVO for 3-6 months if you want relative exposure to obesity share gains and execution quality; thesis breaks if NVO re-accelerates U.S. share or Lilly supply data disappoints.
• For options, favor a defined-risk bull call spread in LLY rather than outright calls; use it only if you expect the next print to confirm sustained demand, because multiple compression is the main downside risk.
• Set an alert on any commentary about GLP-1 supply, payer restrictions, or oral obesity trial/approval timing; those are the highest-probability reversal points for the current bullish narrative.